AnneMNoonanMDPhD, MSc

Oncology • Columbus, OH

Gastrointestinal Cancer

Associate Professor

Join to view full profile

Dr. Noonan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Noonan's full profile

Already have an account?

Office
2050 Kenny Rd
Tower 9th Floor
Columbus, OH 43221
Phone+1 614-293-6529

Fax+1 614-293-9469

Education & Training

University College CorkPhD, 2011 - 2021
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2013
The London School of Hygiene and Tropical Medicine, University of LondonMSc, Clinical Trials, 2007 - 2009
University College Cork Faculty of MedicineClass of 2002

Certifications & Licensure

OH State Medical License 2013 - 2026
MD State Medical License 2012 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Certificate in Palliative CareIrish College of General Practitioners
Royal College of Physicians of IrelandMRCPI Internal Medicine
Royal College of Physicians of Ireland and Royal College of Surgeons of IrelandDiploma in Medicine of the Elderly

Clinical Trials

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer Start of enrollment: 2014 Aug 05
Active, not recruiting
Phase 1
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Start of enrollment: 2015 Oct 01
Completed
Phase 3
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Start of enrollment: 2020 Sep 02
Active, not recruiting
Phase 1
Roles: Sponsor-Investigator, Contact
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer Start of enrollment: 2020 Jun 24
Recruiting
Phase 2
Roles: Contact, Sponsor-Investigator, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

15 citations
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186
Cameron Herting, Matthew R. Farren, Yan Tong, Ziyue Liu, Bert H. O'Neil
Cancer Immunology, Immunotherapy. 2021-06-23
20 citations
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer
Daniel A. Goldstein, Kavya Krishna, Christopher R. Flowers, Bassel F. El-Rayes, Tanios Bekaii-Saab
Medical Oncology. 2016-04-11
25 citations
Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes.
Jordan M. Cloyd, Aslam Ejaz, Chengli Shen, Mary Dillhoff, Terence M. Williams
HPB. 2020-02-13

Lectures

CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020

Press Mentions

Pancreatic Cancer Rates Are Spiking in Women 55 and Under. Experts Don’t yet Know WhyMay 11th, 2023
Post-Diagnosis Dietary Insulinemic Potential and Survival Outcomes Among Colorectal Cancer PatientsAugust 27th, 2020
February Physician of the Month: Anne NoonanFebruary 11th, 2019